HomeCompareENPRF vs MRK

ENPRF vs MRK: Dividend Comparison 2026

ENPRF yields 38461.54% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENPRF wins by $3.5047453194285434e+22M in total portfolio value
10 years
ENPRF
ENPRF
● Live price
38461.54%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.5047453194285434e+22M
Annual income
$34,869,111,860,403,882,000,000,000,000.00
Full ENPRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ENPRF vs MRK

📍 ENPRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENPRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENPRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENPRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENPRF
Annual income on $10K today (after 15% tax)
$3,269,230.77/yr
After 10yr DRIP, annual income (after tax)
$29,638,745,081,343,300,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, ENPRF beats the other by $29,638,745,081,343,300,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENPRF + MRK for your $10,000?

ENPRF: 50%MRK: 50%
100% MRK50/50100% ENPRF
Portfolio after 10yr
$1.7523726597142717e+22M
Annual income
$17,434,555,930,201,941,000,000,000,000.00/yr
Blended yield
99.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ENPRF
No analyst data
Altman Z
-47.1
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENPRF buys
0
MRK buys
0
No recent congressional trades found for ENPRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENPRFMRK
Forward yield38461.54%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$3.5047453194285434e+22M$56.8K
Annual income after 10y$34,869,111,860,403,882,000,000,000,000.00$9,798.13
Total dividends collected$3.5035733915069485e+22M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ENPRF vs MRK ($10,000, DRIP)

YearENPRF PortfolioENPRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$3,856,854$3,846,153.85$11,206$366.19+$3.85MENPRF
2$1,390,486,951$1,386,360,117.24$12,650$502.35+$1390.47MENPRF
3$468,605,187,973$467,117,366,935.83$14,407$694.19+$468605.17MENPRF
4$147,625,030,644,438$147,123,623,093,306.88$16,585$967.82+$147625030.63MENPRF
5$43,474,277,650,870,744$43,316,318,868,081,190.00$19,342$1,363.89+$43474277650.85MENPRF
6$11,968,270,987,896,644,000$11,921,753,510,810,212,000.00$22,913$1,947.19+$11968270987896.62MENPRF
7$3,080,100,013,539,240,000,000$3,067,293,963,582,191,000,000.00$27,662$2,823.89+$3080100013539240.00MENPRF
8$741,038,587,172,289,600,000,000$737,742,880,157,802,600,000,000.00$34,159$4,173.35+$741038587172289664.00MENPRF
9$166,674,143,814,537,900,000,000,000$165,881,232,526,263,560,000,000,000.00$43,337$6,308.80+$166674143814537904128.00MENPRF
10$35,047,453,194,285,434,000,000,000,000$34,869,111,860,403,882,000,000,000,000.00$56,776$9,798.13+$3.5047453194285434e+22MENPRF

ENPRF vs MRK: Complete Analysis 2026

ENPRFStock

Current Water Technologies Inc. develops environmental technologies in Canada, Australia, and the United States. It operates through two segments, Current Water and Pumptronics. The company provides patented and proprietary technologies for the treatment of wastewater and drinking water that are contaminated by metals or nutrients, such as arsenic and nitrate/ammonia associated with the mining, metal processing, chemical, agricultural, municipal, and waste management sectors; and for the recovery of nickel and other valuable metals from waste mill sulphide tailings associated with the mining sector. Its technologies include electro-static deionization, a electrochemical process that lowers the concentration of total dissolved solids in water; ammonia removal technology, a technology used for the removal of dissolved ammonia from industrial and municipal water, including wastewater, storm water, sewage effluent, and mine waste water; NitrEL system, an electrochemical water treatment process that reduces nitrate concentrations in contaminated drinking water, groundwater, and industrial process wastewater streams; AmdEl, an electrochemical system that prevents the oxidation of sulphide minerals in tailings or waste rock; and ExtrEL for the recovery of metals from sulphide tailings and ore. The company was formerly known as ENPAR Technologies Inc. and changed its name to Current Water Technologies Inc. in January 2018. Current Water Technologies Inc. was incorporated in 1996 and is headquartered in Guelph, Canada.

Full ENPRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ENPRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENPRF vs SCHDENPRF vs JEPIENPRF vs OENPRF vs KOENPRF vs MAINENPRF vs JNJENPRF vs ABBVENPRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.